Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

European Journal of Cancer

Volumn 38, Issue 17, 2002, Pages 2272-2278

  Awada, A ^a   Eskens, F A L M ^b   Piccart, M ^a   Cutler, D L ^c   Van der Gaast, A ^b   Bleiberg, H ^a   Wanders, J ^d   Faber, M N ^d   Statkevich, P ^c   Fumoleau, P ^e   Verweij, J ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Farnesyltransferase inhibitor; Pharmacodynamics; Pharmacokinetics; SCH 66336

Indexed keywords

ANTIEMETIC AGENT; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOACCUMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INHIBITION; FATIGUE; FEMALE; HISTOLOGY; HUMAN; IN VIVO STUDY; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA HALF LIFE; PRENYLATION; PRIORITY JOURNAL; SAMPLING; SOLID TUMOR; STEADY STATE; UREMIA; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PIPERIDINES; PYRIDINES;

EID: 0036848118     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00379-9     Document Type: Article

References (20)

1. Prendergast J.C. Targeting farnesyltransferase. is RAS relevant? Am. Soc. Clin. Oncol. 35:1999;22-28. [Educational Book].
2. Gibbs J.B. Ras C-terminal processing enzymes-new drug targets? Cell. 65:1991;1-4.
3. Lowy D.R., Willumsen B.M. Function and regulation of Ras. Annu. Rev. Biochem. 62:1993;851-891.
4. Khosravi-Far R., Der C.J. The Ras signal transduction pathway. Cancer Met. Rev. 13:1994;67-89.
5. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors. Ras research yields a potential cancer therapeutic Cell. 77:1994;175-178.
6. Gibbs J.B., Kohl N.E., Koblan K.S.et al. Farnesyltransferase inhibitors and anti Ras therapy. Breast Cancer Res. Treat. 38:1996;75-83.
7. 2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends Pharmacol. Sci. 18:1997;437-444.
8. Gibbs J.B., Ollif A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37:1997;143-166.
9. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyl transferase. a strategic target for anticancer therapeutic development J. Clin. Oncol. 17:1999;3631-3652.
10. Oliff A. Farnesyl transferase inhibitors. targeting the molecular basis of cancer Biochem. Biophys. Act. 1423:1999;C19-C30.
11. Bos J.L. ras Oncogenes in human cancer. a review Cancer Res. 49:1989;4682-4689.
12. Eskens F.A.L.M., Awada A., Cutler D.L.et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. 19:2001;1167-1175.
13. World Health Organization WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 40. 1979;WHO, Geneva, Switzerland.
14. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd edn. New York, Marcel Dekker, 1982, 409-417.
15. Adjei A.A., Erlichman C.h., Davis J.N.et al. A phase I trial of the farnesyl protein transferase (FPT) inhibitor SCH 66336. evidence for biological and clinical activity Cancer Res. 60:2000;1871-1877.
16. Hurwitz H.I., Colvin O.M., Petros W.P.et al. Phase I and pharmacokinetic study of SCH 66336, a novel FPTI, using a 2-week on, 2-week off schedule. Proc. Am. Soc. Clin. Oncol. 18:1999;156a. (abstr 599).
17. Schellens J., De Klerk G., Swart M.et al. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777. Proc. Am. Soc. Clin. Oncol. 9:2000;184a. (abstr 715).
18. Hudes G., Schol J., Baab A.et al. Phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol. 18:1999;156a. (abstr 601).
19. Zujewski J., Horak I.D., Bol C.J.et al. Phase I and pharmacokinetic study of farnesyl transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18:2000;927-941.
20. Petit T., Izbicka E., Lawrence R.A.et al. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann. Oncol. 10:1999;449-453.